(Q34330678)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23455590%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23455590%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23455590%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Peter Falkai

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23455590%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Andrea Schmitt

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23455590%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Berend Malchow

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23455590%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

1 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23455590%20AND%20SRC:MED&resulttype=core&format=json

European Archives of Psychiatry and Clinical Neuroscience

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23455590%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

263

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23455590%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23455590%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

367-377

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23455590%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00406-013-0399-y

24 February 2020

exact match

0 references

cites work

Recent advances in the phencyclidine model of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Glutamate receptor dysfunction and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

The glutamatergic dysfunction hypothesis for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Provocative tests with psychostimulant drugs in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Mechanism of differential control of NMDA receptor activity by NR2 subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Glutamate receptor ion channels: structure, regulation, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

NMDA receptor subunits: function and pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Metabotropic glutamate receptors: physiology, pharmacology, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Metabotropic glutamate receptors as therapeutic targets for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Corticotropin-releasing hormone, glutamate, and γ-aminobutyric acid in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Beyond monoamines: glutamatergic function in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Emerging role of glutamate in the pathophysiology of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Glutamate-based antidepressants: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Is D-cycloserine a prodrug for D-serine in the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Serine racemase and the serine shuttle between neurons and astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

NMDA- and beta-amyloid1-42-induced neurotoxicity is attenuated in serine racemase knock-out mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Levels of D-serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Role of serine racemase in behavioral sensitization in mice after repeated administration of methamphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Plasma levels of D-serine in Brazilian individuals with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Association analyses of the DAOA/G30 and D-amino-acid oxidase genes in schizophrenia: further evidence for a role in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

The neurobiology of D-amino acid oxidase and its involvement in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

D-serine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

High dose D-serine in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

D-alanine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Synthesis and biological evaluation of D-amino acid oxidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Glycine transporter-1: a new potential therapeutic target for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

The therapeutic potential of glycine transporter-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Glycine transport inhibitors in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Targeting of metabotropic glutamate receptors for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Glutamate signaling in the pathophysiology and therapy of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Increased levels of glutamate in brains from patients with mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

The role of glutamate on the action of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Glutamatergic modulators: the future of treating mood disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

N-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Ketamine for depression: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

A double-blind, placebo-controlled study of memantine in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Neurocognitive impairment in drug-free patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Roles of glutamate signaling in preclinical and/or mechanistic models of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-013-0399-Y

Translating glutamate: from pathophysiology to treatment

21 January 2018

1 reference

12 December 2020

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

1 reference

12 December 2020

NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders

1 reference

12 December 2020

Reduction of cerebrospinal fluid glutamic acid in huntington's chorea and in schizophrenic patients

1 reference

12 December 2020

Effect of MPEP treatment on brain-derived neurotrophic factor gene expression.

1 reference

12 December 2020

Critical role of brain-derived neurotrophic factor in mood disorders

1 reference

12 December 2020

A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression

1 reference

12 December 2020

Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator

1 reference

12 December 2020